{"count": 10, "results": [{"_id": "37303355", "pmid": 37303355, "pmcid": "PMC10257359", "title": "Chronic Kidney Disease of Non-traditional Etiology in a Young Man From Central America: Geography, Poverty, and Uncertain Pathophysiology Create a Formidable Medical Challenge", "journal": "Cureus", "authors": ["Milki AA", "Bechara M", "Lew SQ", "Poon AN"], "date": "2023-05-11T00:00:00Z", "doi": "10.7759/cureus.38876", "meta_date_publication": "2023 May", "meta_volume": "15", "meta_issue": "5", "meta_pages": "e38876", "score": 50258.527, "text_hl": "The @SPECIES_9606 @@@patient@@@ was prescribed @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ at the time of diagnosis. ", "citations": {"NLM": "Milki AA, Bechara M, Lew SQ, Poon AN. Chronic Kidney Disease of Non-traditional Etiology in a Young Man From Central America: Geography, Poverty, and Uncertain Pathophysiology Create a Formidable Medical Challenge Cureus. 2023 May;15(5):e38876. PMID: 37303355", "BibTeX": "@article{37303355, title={Chronic Kidney Disease of Non-traditional Etiology in a Young Man From Central America: Geography, Poverty, and Uncertain Pathophysiology Create a Formidable Medical Challenge}, author={Milki AA and Bechara M and Lew SQ and Poon AN}, journal={Cureus}, volume={15}, number={5}, pages={e38876}}"}}, {"_id": "39577983", "pmid": 39577983, "title": "Has APOL1 kidney disease treatment been hiding in plain sight?", "journal": "Kidney Int", "authors": ["Olabisi OA"], "date": "2024-12-01T00:00:00Z", "doi": "10.1016/j.kint.2024.09.003", "meta_date_publication": "2024 Dec", "meta_volume": "106", "meta_issue": "6", "meta_pages": "1015-1017", "score": 50258.113, "text_hl": "In this issue, Sula Karreci et al. reported that @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ reduced @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ and @DISEASE_Glomerulonephritis @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@ in a @SPECIES_10090 @@@mouse@@@ model of @GENE_APOL1 @GENE_8542 @@@apolipoprotein L1@@@-induced @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@focal segmental glomerulosclerosis@@@, in a genotype-specific manner. ", "citations": {"NLM": "Olabisi OA. Has APOL1 kidney disease treatment been hiding in plain sight? Kidney Int. 2024 Dec;106(6):1015-1017. PMID: 39577983", "BibTeX": "@article{39577983, title={Has APOL1 kidney disease treatment been hiding in plain sight?}, author={Olabisi OA}, journal={Kidney Int}, volume={106}, number={6}, pages={1015-1017}}"}}, {"_id": "21310077", "pmid": 21310077, "pmcid": "PMC3045306", "title": "Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design", "journal": "BMC Nephrol", "authors": ["Trachtman H", "Vento S", "Gipson D", "Wickman L", "Gassman J", "Joy M", "Savin V", "Somers M", "Pinsk M", "Greene T"], "date": "2011-02-10T00:00:00Z", "doi": "10.1186/1471-2369-12-8", "meta_date_publication": "2011 Feb 10", "meta_volume": "12", "meta_issue": "", "meta_pages": "8", "score": 50076.457, "text_hl": "Novel therapies for resistant @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@focal segmental glomerulosclerosis@@@ (@<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FONT@@@) phase II clinical trial: study design", "citations": {"NLM": "Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design BMC Nephrol. 2011 Feb 10;12():8. PMID: 21310077", "BibTeX": "@article{21310077, title={Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design}, author={Trachtman H and Vento S and Gipson D and Wickman L and Gassman J and Joy M and Savin V and Somers M and Pinsk M and Greene T}, journal={BMC Nephrol}, volume={12}, pages={8}}"}}, {"_id": "26198842", "pmid": 26198842, "pmcid": "PMC4511259", "title": "Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group", "journal": "BMC Nephrol", "authors": ["Trachtman H", "Vento S", "Herreshoff E", "Radeva M", "Gassman J", "Stein DT", "Savin VJ", "Sharma M", "Reiser J", "Wei C", "Somers M", "Srivastava T", "Gipson DS"], "date": "2015-07-22T00:00:00Z", "doi": "10.1186/s12882-015-0094-5", "meta_date_publication": "2015 Jul 22", "meta_volume": "16", "meta_issue": "", "meta_pages": "111", "score": 50073.176, "text_hl": "The FONT (Novel Therapies for Resistant @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FSGS@@@) Phase II clinical trial (NCT00814255, Registration date December 22, 2008) was designed to assess the efficacy of @CHEMICAL_Adalimumab @CHEMICAL_MESH:D000068879 @@@adalimumab@@@ and @CHEMICAL_Galactose @CHEMICAL_MESH:D005690 @@@galactose@@@ compared to standard medical therapy which was comprised of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@, and @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@.", "citations": {"NLM": "Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group BMC Nephrol. 2015 Jul 22;16():111. PMID: 26198842", "BibTeX": "@article{26198842, title={Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group}, author={Trachtman H and Vento S and Herreshoff E and Radeva M and Gassman J and Stein DT and Savin VJ and Sharma M and Reiser J and Wei C and Somers M and Srivastava T and Gipson DS}, journal={BMC Nephrol}, volume={16}, pages={111}}"}}, {"_id": "10412735", "pmid": 10412735, "title": "Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable.", "journal": "Kidney Int Suppl", "authors": ["de Boer E", "Navis G", "Wapstra FH", "de Jong PE", "de Zeeuw D"], "date": "1999-07-01T00:00:00Z", "meta_date_publication": "1999 Jul", "meta_volume": "71", "meta_issue": "", "meta_pages": "S42-6", "score": 50071.67, "text_hl": "RESULTS: We found that in @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@adriamycin@@@ @DISEASE_Nephrosis @DISEASE_MESH:D009401 @@@nephrosis@@@, ACEi significantly reduced @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@, @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipids@@@, and blood pressure and provided protection against @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FGS@@@. Treatment modification by increasing the @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ dose resulted in a further reduction of @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FGS@@@ without significant effects on intermediate parameters (@DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@, @DISEASE_Hyperlipidemias @DISEASE_MESH:D006949 @@@hyperlipidemia@@@, and blood pressure), whereas surprisingly, treatment modification by @CHEMICAL_Sodium @CHEMICAL_MESH:D012964 @@@sodium@@@ restriction resulted in a further attenuation of intermediate parameters, without additional protection against @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FGS@@@. ", "citations": {"NLM": "de Boer E, Navis G, Wapstra FH, de Jong PE, de Zeeuw D. Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. Kidney Int Suppl. 1999 Jul;71():S42-6. PMID: 10412735", "BibTeX": "@article{10412735, title={Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable.}, author={de Boer E and Navis G and Wapstra FH and de Jong PE and de Zeeuw D}, journal={Kidney Int Suppl}, volume={71}, pages={S42-6}}"}}, {"_id": "11053977", "pmid": 11053977, "title": "ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy.", "journal": "Exp Nephrol", "authors": ["Wapstra FH", "Navis GJ", "van Goor H", "van den Born J", "Berden JH", "de Jong PE", "de Zeeuw D"], "date": "2001-01-01T00:00:00Z", "doi": "10.1159/000020704", "meta_date_publication": "2001", "meta_volume": "9", "meta_issue": "1", "meta_pages": "21-7", "score": 50066.402, "text_hl": "Treatment was started 6 weeks after disease induction. As expected, @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ reduced blood pressure, @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ and the @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FGS@@@ score. ", "citations": {"NLM": "Wapstra FH, Navis GJ, van Goor H, van den Born J, Berden JH, de Jong PE, de Zeeuw D. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy. Exp Nephrol. 2001;9(1):21-7. PMID: 11053977", "BibTeX": "@article{11053977, title={ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy.}, author={Wapstra FH and Navis GJ and van Goor H and van den Born J and Berden JH and de Jong PE and de Zeeuw D}, journal={Exp Nephrol}, volume={9}, number={1}, pages={21-7}}"}}, {"_id": "12472769", "pmid": 12472769, "title": "Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.", "journal": "Kidney Int", "authors": ["Laverman GD", "Van Goor H", "Henning RH", "De Jong PE", "De Zeeuw D", "Navis G"], "date": "2003-01-01T00:00:00Z", "doi": "10.1046/j.1523-1755.2003.00708.x", "meta_date_publication": "2003 Jan", "meta_volume": "63", "meta_issue": "1", "meta_pages": "64-71", "score": 50065.477, "text_hl": "@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@LIS@@@ (18 +/- 6) reduced @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FGS@@@ significantly. ", "citations": {"NLM": "Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int. 2003 Jan;63(1):64-71. PMID: 12472769", "BibTeX": "@article{12472769, title={Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.}, author={Laverman GD and Van Goor H and Henning RH and De Jong PE and De Zeeuw D and Navis G}, journal={Kidney Int}, volume={63}, number={1}, pages={64-71}}"}}, {"_id": "23805377", "pmid": 23805377, "pmcid": "PMC3693487", "title": "Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways", "journal": "Clin Kidney J", "authors": ["Afshinnia F", "Vega-Warner V", "Killen P"], "date": "2013-04-01T00:00:00Z", "doi": "10.1093/ckj/sft010", "meta_date_publication": "2013 Apr", "meta_volume": "6", "meta_issue": "2", "meta_pages": "208-210", "score": 50064.215, "text_hl": "Association of @GENE_NF1 @GENE_4763 @@@NF1@@@ with @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@focal segmental glomerulosclerosis@@@ (@<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@FSGS@@@) is quite rare. ", "citations": {"NLM": "Afshinnia F, Vega-Warner V, Killen P. Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways Clin Kidney J. 2013 Apr;6(2):208-210. PMID: 23805377", "BibTeX": "@article{23805377, title={Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways}, author={Afshinnia F and Vega-Warner V and Killen P}, journal={Clin Kidney J}, volume={6}, number={2}, pages={208-210}}"}}, {"_id": "9165371", "pmid": 9165371, "title": "Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats.", "journal": "Jpn J Pharmacol", "authors": ["Shinosaki T", "Takagawa I", "Sunagawa N", "Yonetani Y", "Kurihara H"], "date": "1997-04-01T00:00:00Z", "doi": "10.1254/jjp.73.337", "meta_date_publication": "1997 Apr", "meta_volume": "73", "meta_issue": "4", "meta_pages": "337-45", "score": 50063.6, "text_hl": "These results indicate that @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ treatment attenuates @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ by ameliorating the anionic charge barrier on the glomerular basement membrane and that it also protects against the development of @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@chronic renal disease@@@ with @<m>DISEASE_Glomerulosclerosis_Focal_Segmental</m> @DISEASE_MESH:D005923 @@@segmental glomerular sclerosis@@@, although AII depletion during the acute @DISEASE_Nephrotic_Syndrome @DISEASE_MESH:D009404 @@@nephrotic@@@ stage exacerbates the @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@renal damage@@@ in PAN @DISEASE_Nephrosis @DISEASE_MESH:D009401 @@@nephrosis@@@ of unilaterally nephrectomized @SPECIES_10116 @@@rats@@@.", "citations": {"NLM": "Shinosaki T, Takagawa I, Sunagawa N, Yonetani Y, Kurihara H. Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Jpn J Pharmacol. 1997 Apr;73(4):337-45. PMID: 9165371", "BibTeX": "@article{9165371, title={Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats.}, author={Shinosaki T and Takagawa I and Sunagawa N and Yonetani Y and Kurihara H}, journal={Jpn J Pharmacol}, volume={73}, number={4}, pages={337-45}}"}}, {"_id": "30148914", "pmid": 30148914, "title": "[Hepatocellular damage, proteinuria and autoimmunity: multisystemic disorder or coexistence of diseases?]", "journal": "Rev Med Chil", "authors": ["Herrera P", "Ruiz A", "Carpio D", "Ardiles L"], "date": "2018-06-01T00:00:00Z", "doi": "10.4067/s0034-98872018000600808", "meta_date_publication": "2018 Jun", "meta_volume": "146", "meta_issue": "6", "meta_pages": "808-812", "score": 50058.54, "text_hl": "The use of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ resulted in a significative reduction of @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ and, after 30 months of follow up, he continues with @CHEMICAL_Azathioprine @CHEMICAL_MESH:D001379 @@@azathioprine@@@, @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and a low @CHEMICAL_Prednisone @CHEMICAL_MESH:D011241 @@@prednisone@@@ dose without evidence of @DISEASE_Liver_Diseases @DISEASE_MESH:D008107 @@@liver or kidney disease@@@ activity.", "citations": {"NLM": "Herrera P, Ruiz A, Carpio D, Ardiles L. [Hepatocellular damage, proteinuria and autoimmunity: multisystemic disorder or coexistence of diseases?] Rev Med Chil. 2018 Jun;146(6):808-812. PMID: 30148914", "BibTeX": "@article{30148914, title={[Hepatocellular damage, proteinuria and autoimmunity: multisystemic disorder or coexistence of diseases?]}, author={Herrera P and Ruiz A and Carpio D and Ardiles L}, journal={Rev Med Chil}, volume={146}, number={6}, pages={808-812}}"}}]}